Weight regain after stopping GLP-1 drugs: what the evidence says

What's this video probably claiming?

Based on the caption, Sky News is reporting on Rosie Parsons, who lost eight stone on a GLP-1 receptor agonist (likely tirzepatide or semaglutide), then regained roughly half that weight within four months of stopping treatment. The caption also references a BMJ statistic about average outcomes after discontinuation. The framing appears to be investigative journalism asking a legitimate question: what actually happens physiologically when people come off these drugs? This is a well-documented clinical phenomenon, not a scare story. The video appears to be raising reasonable concerns about long-term treatment dependency, the rebound effect, and whether the NHS or patients are being adequately counselled about what stopping looks like. That's fair reporting territory. The risk is that individual anecdotes like Rosie's get treated as representative when the data shows a range of outcomes depending on diet, activity, and how long someone was on treatment.

What does the science actually show?

The regain data is real and fairly consistent across multiple trials. The STEP 1 Extension trial (Wilding et al., 2022, New England Journal of Medicine) followed participants who completed 68 weeks of semaglutide 2.4mg and then stopped. Within 12 months of stopping, participants regained two-thirds of their prior weight loss on average, and cardiometabolic improvements largely reversed. A separate analysis of tirzepatide (the SURMOUNT-4 trial, Aronne et al., 2024, JAMA) showed that switching from tirzepatide to placebo resulted in participants regaining approximately half their lost weight over 52 weeks, while those who continued the drug maintained their loss. The biological explanation is not laziness or poor willpower. GLP-1 receptor agonists suppress appetite partly by mimicking satiety hormones. When you stop, appetite hormonal signalling reverts. Body weight set-point mechanisms, including ghrelin elevation and leptin resistance, reassert themselves. The drugs were treating a chronic condition, not curing it.

Where does the social media noise diverge from clinical reality?

The problem with how this story tends to travel on social media is the framing of regain as either a scandal or a surprise. It is neither. Obesity is classified as a chronic, relapsing condition by organisations including the World Obesity Federation. The regain after stopping GLP-1 drugs is clinically analogous to blood pressure rising again when you stop antihypertensives. Nobody calls that a failure of the medication. What gets lost in the noise is that regain trajectories vary significantly. Some patients who combine these drugs with sustained behavioural change maintain a larger proportion of their loss. The Rosie Parsons case, losing eight stone and regaining four in four months, sits at the more dramatic end of outcomes and may reflect particularly rapid discontinuation or absence of structured lifestyle support post-treatment. Using one person's story to define the category is exactly the kind of thing investigative health journalism should avoid, though Sky News, to their credit, appears to be contextualising with BMJ data.

What should you actually know?

If you are on or considering a GLP-1 receptor agonist, here is what the clinical literature actually supports. First, these drugs work while you take them. The STEP and SURMOUNT trial families show average weight losses of 15 to 22 percent of body weight with continued use. Second, most people will regain significant weight after stopping, not because the drug failed, but because the underlying condition persists. Third, the question of indefinite versus time-limited treatment is genuinely unsettled in the literature and in clinical practice, and the NHS is still working out prescribing frameworks. Fourth, stopping abruptly without a plan is associated with worse outcomes than tapering with dietary support in place. If your prescriber has not discussed a discontinuation plan with you, that is a conversation worth having before you stop, not after. Individual results like Rosie's are real but not universal, and the BMJ average the caption references is more useful than any single case.